VIVUS Inc. (VVUS)

4.29
NASDAQ : Health Technology
Prev Close 4.17
Day Low/High 4.14 / 4.31
52 Wk Low/High 2.15 / 5.78
Avg Volume 115.60K
Exchange NASDAQ
Shares Outstanding 10.64M
Market Cap 44.38M
EPS -3.50
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Vivus downgraded at Piper Jaffray

Companies Ripe for Activism

Companies Ripe for Activism

Hedge fund manager Gregory Taxin of Clinton Group talks about when companies hit a critical point that makes them ripe for activism.

2 Ways to Play Vivus

2 Ways to Play Vivus

The short-term picture has changed.

Viva La Vivus?

Viva La Vivus?

This looks ready to make a move higher.

Beware of 'Earnings Torpedos'

Some of the market's favorite stocks have entered a danger zone.

Vivus downgraded at Lazard

Vivus estimates lowered at Jefferies

Vivus cut from US 1 List at BofA/Merrill

Vivus downgraded at Credit Suisse

Playing Obesity Drugs the ETF Way

Playing Obesity Drugs the ETF Way

Liquidity is key, and one ETF stands above the rest.

Obesity Treatment Shift Could Aid Stocks

Obesity Treatment Shift Could Aid Stocks

Obesity costs are a  pain point, which  often create good investments.

Vivus downgraded at Lazard

The 5 Dumbest Things on Wall Street: March 1

The 5 Dumbest Things on Wall Street: March 1

Here is this week's roundup of the dumbest actions on Wall Street.

Vivus estimates, target reduced at JMP

The Next Big Thing in Biotech

The Next Big Thing in Biotech

Adam Feuerstein, senior columnist for TheStreet, says biotech earnings are the next big thing to watch in biotech.

Cramer: ADP Report is Irrelevant

Cramer: ADP Report is Irrelevant

Jim Cramer says we should throw out the ADP report and the BLS should out source the work to TIBCO.

Vivus target reduced at Credit Suisse

Weight Loss Pills Not a Threat, Says Medifast CEO

Weight Loss Pills Not a Threat, Says Medifast CEO

Mike MacDonald, CEO of Medifast, says the company's new franchise strategy is propelling its stock and recently approved weight loss pills are not a threat.

The Next Big Thing in Biotech: Obesity Drugs

The Next Big Thing in Biotech: Obesity Drugs

Senior columnist Adam Feuerstein says obesity drugs are the next big thing to watch in biotech.

Vivus upgraded at Lazard

The Next Big Thing in Biotech: FDA Approvals

The Next Big Thing in Biotech: FDA Approvals

Senior columnist Adam Feuerstein says post-FDA approval trading is the next big thing to watch in biotech.

VIVUS upgraded at Jefferies

The Next Big Thing in Biotech: Vivus

The Next Big Thing in Biotech: Vivus

Adam Feuerstein, senior columnist for TheStreet, says Vivus is the next big thing in biotech.

Don't Chase ARNA

Don't Chase ARNA

The stock is way too extended to consider buying at current levels.

Biotechs Get Interesting

The sector has been attracting the hot money for a couple weeks.

Slow, but Positive

The longer this action persists, the more anxious folks will be to put idle cash to work.